# The Effect of Benralizumab on Exercise-induced Bronchoconstriction

> **NCT03327701** · PHASE3 · UNKNOWN · sponsor: **Louis-Philippe Boulet** · enrollment: 40 (estimated)

## Conditions studied

- Asthma, Exercise-Induced

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT03327701
- **Lead sponsor:** Louis-Philippe Boulet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12
- **Primary completion:** 2019-12
- **Final completion:** 2020-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03327701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03327701, "The Effect of Benralizumab on Exercise-induced Bronchoconstriction". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03327701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*